Bristol Myers Squibb Promotes Health Equity with 100 Percent of Marketed Products Now Supported by Access Plans
Bristol Myers Squibb (BMY) has announced that 100% of its marketed products are now supported by access plans, as part of its 10-year ASPIRE strategy to promote health equity and increase access to medicines in low- and middle-income countries (LMICs). The company aims to reach over 208,000 patients in LMICs by 2033. BMS is collaborating with the Access to Oncology Medicines (ATOM) Coalition to make Opdivo (nivolumab) available in select countries including Pakistan, Rwanda, and Zambia. This initiative is part of BMS's broader commitment to health equity and its Environmental, Social and Governance (ESG) strategy, focusing on reducing quality-of-care gaps and strengthening health systems globally.
Bristol Myers Squibb (BMY) ha annunciato che il 100% dei suoi prodotti commercializzati è ora supportato da piani di accesso, come parte della sua strategia ASPIRE decennale per promuovere l'equità sanitaria e aumentare l'accesso ai farmaci nei paesi a basso e medio reddito (LMIC). L'azienda mira a raggiungere oltre 208.000 pazienti nei LMIC entro il 2033. BMS sta collaborando con la Coalizione Accesso ai Farmaci Oncologici (ATOM) per rendere Opdivo (nivolumab) disponibile in alcuni paesi tra cui Pakistan, Ruanda e Zambia. Questa iniziativa fa parte dell'impegno più ampio di BMS per l'equità sanitaria e della sua strategia Ambientale, Sociale e di Governance (ESG), focalizzandosi sulla riduzione delle disparità nella qualità dell'assistenza e sul rafforzamento dei sistemi sanitari a livello globale.
Bristol Myers Squibb (BMY) ha anunciado que el 100% de sus productos comercializados ahora cuenta con planes de acceso, como parte de su estrategia ASPIRE de 10 años para promover la equidad en salud y aumentar el acceso a medicamentos en países de ingresos bajos y medianos (LMIC). La empresa tiene como objetivo alcanzar a más de 208,000 pacientes en LMIC para 2033. BMS está colaborando con la Coalición de Acceso a Medicamentos Oncológicos (ATOM) para hacer que Opdivo (nivolumab) esté disponible en ciertos países, incluidos Pakistán, Ruanda y Zambia. Esta iniciativa es parte del compromiso más amplio de BMS con la equidad en salud y su estrategia de Medio Ambiente, Social y Gobernanza (ESG), centrada en reducir las disparidades en la calidad de la atención y fortalecer los sistemas de salud a nivel global.
Bristol Myers Squibb (BMY)는 자사가 판매하는 모든 제품의 100%가 이제 접근 계획의 지원을 받고 있다고 발표했습니다. 이는 건강 형평성을 촉진하고 저소득 및 중간 소득 국가(LMIC)에서 의약품 접근성을 높이기 위한 10년 ASPIRE 전략의 일환입니다. 이 회사는 2033년까지 LMIC에서 208,000명 이상의 환자에게 도달하는 것을 목표로 하고 있습니다. BMS는 파키스탄, 르완다 및 잠비아를 포함한 특정 국가에서 Opdivo(nivolumab)를 이용 가능하게 하기 위해 암 치료 약물 접근(ATOM) 연합과 협력하고 있습니다. 이 이니셔티브는 BMS의 건강 형평성에 대한 더 넓은 약속과 환경, 사회 및 거버넌스(ESG) 전략의 일환으로, 전 세계적으로 치료 품질 격차를 줄이고 건강 시스템을 강화하는 데 초점을 맞추고 있습니다.
Bristol Myers Squibb (BMY) a annoncé que 100 % de ses produits commercialisés sont désormais soutenus par des plans d'accès, dans le cadre de sa stratégie ASPIRE de 10 ans visant à promouvoir l'équité en santé et à augmenter l'accès aux médicaments dans les pays à revenu faible et intermédiaire (LMIC). L'entreprise vise à atteindre plus de 208 000 patients dans les LMIC d'ici 2033. BMS collabore avec la Coalition pour l'accès aux médicaments oncologiques (ATOM) pour rendre Opdivo (nivolumab) disponible dans certains pays, y compris le Pakistan, le Rwanda et la Zambie. Cette initiative s'inscrit dans l'engagement plus large de BMS en faveur de l'équité en santé et de sa stratégie en matière d'environnement, de social et de gouvernance (ESG), en se concentrant sur la réduction des écarts de qualité des soins et sur le renforcement des systèmes de santé à l'échelle mondiale.
Bristol Myers Squibb (BMY) hat angekündigt, dass 100% seiner vermarkteten Produkte jetzt von Zugangsplänen unterstützt werden, im Rahmen seiner 10-jährigen ASPIRE-Strategie zur Förderung der gesundheitlichen Chancengleichheit und zur Erhöhung des Zugangs zu Medikamenten in einkommensschwachen und mittleren Ländern (LMIC). Das Unternehmen strebt an, bisher über 208.000 Patienten in LMICs bis 2033 zu erreichen. BMS arbeitet mit der Access to Oncology Medicines (ATOM) Coalition zusammen, um Opdivo (Nivolumab) in ausgewählten Ländern wie Pakistan, Ruanda und Sambia verfügbar zu machen. Diese Initiative ist Teil des umfassenderen Engagements von BMS für gesundheitliche Chancengleichheit und seiner Umwelt-, Sozial- und Unternehmensführungs-(ESG)-Strategie, die sich auf die Verringerung der Qualitätslücken in der Gesundheitsversorgung und die Stärkung der Gesundheitssysteme weltweit konzentriert.
- 100% of marketed products now supported by access plans
- Goal to reach over 208,000 patients in LMICs by 2033
- Collaboration with ATOM Coalition to expand access to Opdivo in select countries
- Development of tailored strategies to increase affordability and availability of medicines in LMICs
- None.
Insights
Bristol Myers Squibb's (BMS) ASPIRE initiative represents a significant step towards addressing global health inequities, particularly in low- and middle-income countries (LMICs). The commitment to support 100% of marketed products with access plans is a laudable goal, but its real-world impact remains to be seen.
The collaboration with the ATOM Coalition to make Opdivo™ available in select LMICs is promising, potentially setting a precedent for immuno-oncology access in resource- settings. However, the true measure of success will be in the implementation and scalability of these access plans.
While BMS's goal to reach 208,000 patients in LMICs by 2033 is commendable, it's important to contextualize this number against the total patient population in need. The pharmaceutical industry must balance profit motives with global health responsibilities and BMS's approach could influence industry norms.
Investors should monitor the financial implications of this initiative, including potential impacts on revenue streams and long-term market expansion in emerging economies. The success of ASPIRE could position BMS as a leader in corporate social responsibility within the pharmaceutical sector, potentially enhancing its reputation and stakeholder relationships.
BMS's comprehensive approach to global market access through ASPIRE is strategically sound, potentially opening new revenue streams in previously underserved markets. The initiative's focus on affordability and availability in LMICs could lead to increased market share and brand loyalty in these regions over time.
The company's collaboration with the ATOM Coalition for Opdivo™ distribution demonstrates a nuanced understanding of the complexities involved in penetrating LMIC markets. This partnership model could prove important in navigating regulatory hurdles and establishing distribution networks in challenging environments.
From an investor's perspective, the long-term vision of ASPIRE (10 years) suggests a commitment to sustainable growth in emerging markets. However, it's important to monitor the balance between access initiatives and maintaining profit margins. The success of this strategy could hinge on BMS's ability to leverage economies of scale and potentially develop market-specific pricing models.
While the immediate financial impact may be , the long-term potential for market expansion and reputational benefits could translate into tangible value for shareholders. Investors should watch for key performance indicators related to LMIC market penetration and revenue growth in these regions as indicators of ASPIRE's success.
10-year strategy to advance access to our innovative treatments and help patients in low- and middle-income countries (LMICs)
NORTHAMPTON, MA / ACCESSWIRE / July 25, 2024 / At BMS, our vision to transform patients' lives through science extends to all patients. That is why we have a long-standing commitment to promote health equity and help people in underserved communities access the care and medicines they need.
We built on this commitment with a 10-year strategy to help patients in LMICs (low- and middle-income countries) live healthier lives, called ASPIRE, which stands for Accessibility, Sustainability, Patient-centric, Impact, Responsibility and Equity. ASPIRE will help us achieve our goal to reach more than 208,000 patients in LMICs by 2033. The effort reflects our unwavering focus on operating responsibly and sustainably.
As part of ASPIRE, BMS is developing tailored strategies to increase affordability and availability of its medicines in LMICs. Our work to help ensure patients who need our potentially life-saving medicines can access them begins by ensuring that 100 percent of our marketed products are supported by access plans.
Today, we have defined access pathways for every country in which our medicines may be available to patients and have achieved our goal of 100 percent of our marketed products be supported by access plans.
The imbalance in healthcare access is just one of the systemic barriers faced by the world's most vulnerable populations, where worse health outcomes and lack of economic opportunities keep individuals and entire communities from achieving their full potential.
BMS is leading the way for access to immuno-oncology therapies in LMICs by collaborating with the Access to Oncology Medicines (ATOM) Coalition. BMS joined the ATOM Coalition as a founding supporter at its launch in 2022. Working with the ATOM Coalition and their partners, BMS will make Opdivo™ (nivolumab) available via a safe, scalable and sustainable access model in select countries including Pakistan, Rwanda and Zambia while working to develop an integrated pathway that can expand access in multiple LMICs by 2026.
By investing in solutions that reduce quality-of-care gaps and strengthen health systems, BMS will help drive equitable access to innovative medicines to patients around the world, regardless of where patients live. Enabling timely access to innovative medicines in LMICs is part of BMS' commitment to health equity globally and our Environmental, Social and Governance (ESG) strategy.
To learn more, read our press release.
Contact Info:
Spokesperson: Bristol Myers Squibb Company
Website: https://www.3blmedia.com/profiles/bristol-myers-squibb-company
Email: info@3blmedia.com
SOURCE: Bristol Myers Squibb Company
View the original press release on accesswire.com
FAQ
What is Bristol Myers Squibb's (BMY) ASPIRE strategy?
How is Bristol Myers Squibb (BMY) improving access to its medicines in LMICs?
What is Bristol Myers Squibb's (BMY) goal for patient reach in LMICs by 2033?
Which Bristol Myers Squibb (BMY) product is being made available through the ATOM Coalition?
